Overcoming Real World Challenges in the Management
of Metastatic Bladder Cancer: How Advances in
Immunotherapy are Improving Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 10, 2018 to March 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck & Co

Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. Long-term survival for patients diagnosed with metastatic bladder cancer is poor, with only 5% of patients surviving for 5 years or more. Due to the role of the immune system in oncogenesis, therapy has become clearer across cancer types, and new approaches are emerging with important benefits in metastatic bladder cancer. In particular, immune checkpoint inhibitors such as programmed death-1 (PD-1), PD-ligand 1 (PD-L1), and cytotoxic T lymphocyte–associated protein 4 (CTLA-4) inhibitors are changing the treatment paradigm. Checkpoint inhibitors have shown efficacy in patients with metastatic bladder cancer in both the second-line setting and the first-line settings. These inhibitors target proteins that are expressed at high levels on some cancer cells, while others target immune cells. All of these new options allow the immune system to be more active against tumor cells. As immune checkpoint blockade inhibitors in the treatment of advanced bladder cancer have demonstrated significant enhancements to clinical outcomes.

Upon Completion of this activity, participants will be able to:

  • Analyze immunotherapy options in the first-line treatment of metastatic bladder cancer

  • Assess the safety & efficacy data of Anti–PD-1 immunotherapy in metastatic bladder cancer

  • Explore best practices for the incorporation of immune checkpoint inhibitors into existing treatment paradigms

  • Discuss strategies for the prevention, detection, and optimal management of immune-related adverse effects

Faculty: Matthew Campbell, MD, MS
Assistant Professor
Department of Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center


Dr. Campbell serves on an advisory board for AstraZeneca, Eisai and EMD Serono. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck & Co

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue